Acetylation mimic of lysine 280 exacerbates human Tau neurotoxicity in vivo

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Gorsky, Marianna Karina ^a,b   Burnouf, Sylvie ^a,b   Dols, Jacqueline ^a,b   Mandelkow, Eckhard ^c,d   Partridge, Linda ^a,e  

^a MAX PLANCK INSTITUTE FOR BIOLOGY OF AGEING   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^d CENTER OF ADVANCED EUROPEAN STUDIES AND RESEARCH CAESAR   (Germany)

^e MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LYSINE; MAPT PROTEIN, HUMAN; NEUROTOXIN; TAU PROTEIN;

ACETYLATION; ALZHEIMER DISEASE; ANIMAL; DISEASE MODEL; DROSOPHILA; FEMALE; HUMAN; METABOLISM; PATHOLOGY; PROTEIN PROCESSING; PROTEINOSIS; TRANSGENIC ANIMAL;

ACETYLATION; ALZHEIMER DISEASE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; DROSOPHILA; FEMALE; HUMANS; LYSINE; NEUROTOXINS; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN PROCESSING, POST-TRANSLATIONAL; TAU PROTEINS;

EID: 84960510155     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22685     Document Type: Article

References (38)

1. Cook, C., Stankowski, J. N., Carlomagno, Y., Stetler, C. & Petrucelli, L. Acetylation: a new key to unlock tau's role in neurodegeneration. Alzheimers Res Ter 6, 29 (2014).
2. Cohen, T. J. et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2, 252 (2011).
3. Min, S. W. et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953-66 (2010).
4. Cook, C. et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Genet 23, 104-16 (2014).
5. Min, S. W. et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive defcits. Nat Med 21, 1154-62 (2015).
6. Kamah, A. et al. Nuclear magnetic resonance analysis of the acetylation pattern of the neuronal Tau protein. Biochemistry 53, 3020-32 (2014).
7. Irwin, D. J. et al. Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain 135, 807-18 (2012).
8. Grinberg, L. T. et al. Argyrophilic grain disease difers from other tauopathies by lacking tau acetylation. Acta Neuropathol 125, 581-93 (2013).
9. Barghorn, S. et al. Structure, microtubule interactions, and paired helical flament aggregation by tau mutants of frontotemporal dementias. Biochemistry 39, 11714-21 (2000).
10. Goedert, M. & Jakes, R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta 1739, 240-50 (2005).
11. Mizielinska, S. et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 345, 1192-4 (2014).
12. Burnouf, S., Gorsky, M. K., Dols, J., Gronke, S. & Partridge, L. Abeta43 is neurotoxic and primes aggregation of Abeta40 in vivo. Ac ta Neuropathol 130, 35-47 (2015).
13. Wittmann, C. W. et al. Tauopathy in Drosophila: neurodegeneration without neurofbrillary tangles. Science 293, 711-4 (2001).
14. Jackson, G. R. et al. Human wild-type tau interacts with wingless pathway components and produces neurofbrillary pathology in Drosophila. Neuron 34, 509-19 (2002).
15. Banks, A. S. et al. Dissociation of the glucose and lipid regulatory functions of FoxO1 by targeted knockin of acetylation-defective alleles in mice. Cell Metab 14, 587-97 (2011).
16. Waluk, D. P., Sucharski, F., Sipos, L., Silberring, J. & Hunt, M. C. Reversible lysine acetylation regulates activity of human glycine N-acyltransferase-like 2 (hGLYATL2): implications for production of glycine-conjugated signaling molecules. J Biol Chem 287, 16158-67 (2012).
17. de Boor, S. et al. Small GTP-binding protein Ran is regulated by posttranslational lysine acetylation. Proc Natl Acad Sci USA 112, E3679-88 (2015).
18. Hecht, A., Laroche, T., Strahl-Bolsinger, S., Gasser, S. M. & Grunstein, M. Histone H3 and H4 N-termini interact with SIR3 and SIR4 proteins: a molecular model for the formation of heterochromatin in yeast. Cell 80, 583-92 (1995).
19. Markstein, M., Pitsouli, C., Villalta, C., Celniker, S. E. & Perrimon, N. Exploiting position efects and the gypsy retrovirus insulator to engineer precisely expressed transgenes. Nat Genet 40, 476-83 (2008).
20. Franceschini, N., Kirschfeld, K. & Minke, B. Fluorescence of photoreceptor cells observed in vivo. Science 213, 1264-7 (1981).
21. Lasagna-Reeves, C. A. et al. Identifcation of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J 26, 1946-59 (2012).
22. Hanger, D. P., Anderton, B. H. & Noble, W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. T r e n d s Mol Med 15, 112-9 (2009).
23. Bouleau, S. & Tricoire, H. Drosophila models of Alzheimer's disease: advances, limits, and perspectives. J Alzheimers Dis 45, 1015-38 (2015).
24. Folwell, J. et al. Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer's disease. Exp Neurol 223, 401-9 (2010).
25. Fatouros, C. et al. Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity. Hum Mol Genet 21, 3587-603 (2012).
26. Van der Jeugd, A. et al. Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. Acta Neuropathol 123, 787-805 (2012).
27. Eckermann, K. et al. The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J Biol Chem 282, 31755-65 (2007).
28. Rizzu, P. et al. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am J Hum Genet 64, 414-21 (1999).
29. Tepper, K. et al. Oligomer formation of tau protein hyperphosphorylated in cells. J Biol Chem 289, 34389-407 (2014).
30. Augustinack, J. C., Schneider, A., Mandelkow, E. M. & Hyman, B. T. Specifc tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103, 26-35 (2002).
31. Buee, L., Bussiere, T., Buee-Scherrer, V., Delacourte, A. & Hof, P. R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33, 95-130 (2000).
32. Colodner, K. J. & Feany, M. B. Glial fbrillary tangles and JAK/STAT-mediated glial and neuronal cell death in a Drosophila model of glial tauopathy. J Neurosci 30, 16102-13 (2010).
33. Kfoury, N., Holmes, B. B., Jiang, H., Holtzman, D. M. & Diamond, M. I. Trans-cellular propagation of Tau aggregation by fbrillar species. J Biol Chem 287, 19440-51 (2012).
34. Dujardin, S. et al. Ectosomes: a new mechanism for non-exosomal secretion of tau protein. PLoS One 9, e100760 (2014).
35. Asai, H. et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci 18, 1584-93 (2015).
36. Osterwalder, T., Yoon, K. S., White, B. H. & Keshishian, H. A conditional tissue-specifc transgene expression system using inducible GAL4. Proc Natl Acad Sci USA 98, 12596-601 (2001).
37. Gustke, N., Trinczek, B., Biernat, J., Mandelkow, E. M. & Mandelkow, E. Domains of tau protein and interactions with microtubules. Biochemistry 33, 9511-22 (1994).
38. Greene, J. C. et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA 100, 4078-83 (2003).